Table 2.

PTLD risk associated with HCV status at the time of transplantation among 210 763 solid organ transplant recipients

	HCV+	HCV status unknown
Unadjusted	0.63 (0.51-0.78)	0.88 (0.76-1.02)
Adjusted for age, sex, race/ethnicity, and education	0.84 (0.68-1.05)	0.84 (0.73-0.98)
Additional adjustments
Organ type (HL, KP, liver, other)	0.78 (0.62-0.97)	0.81 (0.70-0.94)
Indication for transplantation	0.83 (0.65-1.05)	0.84 (0.72-0.97)
Degree of HLA mismatch (score: 0-6)	0.75 (0.61-0.94)	0.81 (0.70-0.94)
Donor type (cadaveric/living)	0.78 (0.63-0.97)	0.82 (0.71-0.95)
Use of any induction medication	0.85 (0.68-1.05)	0.86 (0.74-1.00)
Use of specified induction medications: polyclonal antibodies or other	0.85 (0.69-1.06)	0.86 (0.74-1.00)
Use of any maintenance medication	0.85 (0.68-1.05)	0.86 (0.74-1.00)
Use of specified maintenance medications: steroids, antimetabolites, calcineurin inhibitor, or TOR inhibitors	0.85 (0.69-1.06)	0.85 (0.73-0.99)
Use of any antirejection medication	0.84 (0.68-1.04)	0.84 (0.73-0.98)
Use of specified antirejection medications: polyclonal antibodies or other	0.84 (0.68-1.04)	0.84 (0.73-0.98)
Use of any induction, maintenance, and antirejection immunosuppresion medications	0.84 (0.68-1.05)	0.87 (0.75-1.01)
Use of specified induction, maintenance, and antirejection immunosuppression medications	0.85 (0.69-1.06)	0.87 (0.75-1.01)

Data are HR (95% CI). HCV⁻ recipients were used as the referent group in all analyses.

HL indicates heart and/or lung; and KP, kidney and/or pancreas.